Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

The influence of hepatic function on prostate cancer outcomes after radical prostatectomy

Prostate Cancer and Prostatic Diseases volume 13, pages 173–177 (2010)Cite this article

Subjects

Abstract

Prostate growth is dependent on circulating androgens, which can be influenced by hepatic function. Liver disease has been suggested to influence prostate cancer (CaP) incidence. However, the effect of hepatic function on CaP outcomes has not been investigated. A total of 1181 patients who underwent radical prostatectomy (RP) between 1988 and 2008 at four Veterans Affairs hospitals that comprise the Shared Equal Access Regional Cancer Hospital database and had available liver function test (LFT) data were included in the study. Independent associations of LFTs with unfavorable pathological features and biochemical recurrence were determined using logistic and Cox regression analyses. Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) levels were elevated in 8.2 and 4.4% of patients, respectively. After controlling for CaP features, logistic regression revealed a significant association between SGOT levels and pathological Gleason sum ⩾7(4+3) cancer (odds ratio=2.12; 95% confidence interval=1.11–4.05; P=0.02). Mild hepatic dysfunction was significantly associated with adverse CaP grade, but was not significantly associated with other adverse pathological features or biochemical recurrence in a cohort of men undergoing RP. The effect of moderate-to-severe liver disease on disease outcomes in CaP patients managed non-surgically remains to be investigated.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ . Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996; 88: 1118–1126.

    Article  CAS  PubMed  Google Scholar 

  2. Severi G, Morris HA, MacInnis RJ, English DR, Tilley W, Hopper JL et al. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 86–91.

    Article  CAS  PubMed  Google Scholar 

  3. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215–224.

    Article  CAS  PubMed  Google Scholar 

  4. Bañez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 2007; 298: 2275–2280.

    Article  PubMed  Google Scholar 

  5. Freedland SJ, Platz EA, Presti Jr JC, Aronson WJ, Amling CL, Kane CJ et al. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol 2006; 175: 500–504.

    Article  PubMed  Google Scholar 

  6. Presti Jr JC, Lee U, Brooks JD, Terris MK . Lower body mass index is associated with a higher prostate cancer detection rate and less favorable pathological features in a biopsy population. J Urol 2004; 171: 2199–2202.

    Article  PubMed  Google Scholar 

  7. Maruyama Y, Adachi Y, Aoki N, Suzuki Y, Shinohara H, Yamamoto T . Mechanism of feminization in male patients with non-alcoholic liver cirrhosis: role of sex hormone-binding globulin. Gastroenterol Jpn 1991; 26: 435–439.

    Article  CAS  PubMed  Google Scholar 

  8. Luppa PB, Thaler M, Schulte-Frohlinde E, Schreiegg A, Huber U, Metzger J . Unchanged androgen-binding properties of sex hormone-binding globulin in male patients with liver cirrhosis. Clin Chem Lab Med 2006; 44: 967–973.

    Article  CAS  PubMed  Google Scholar 

  9. Lindholm J, Fabricius-Bjerre N, Bahnsen M, Boiesen P, Hagen C, Christensen T . Sex steroids and sex-hormone binding globulin in males with chronic alcoholism. Eur J Clin Invest 1978; 8: 273–276.

    Article  CAS  PubMed  Google Scholar 

  10. Wang YJ, Wu JC, Lee SD, Tsai YT, Lo KJ . Gonadal dysfunction and changes in sex hormones in postnecrotic cirrhotic men: a matched study with alcoholic cirrhotic men. Hepatogastroenterology 1991; 38: 531–534.

    CAS  PubMed  Google Scholar 

  11. Dennis LK . Meta-analysis for combining relative risks of alcohol consumption and prostate cancer. Prostate 2000; 42: 56–66.

    Article  CAS  PubMed  Google Scholar 

  12. Breslow RA, Weed DL . Review of epidemiologic studies of alcohol and prostate cancer: 1971–1996. Nutr Cancer 1998; 30: 1–13.

    Article  CAS  PubMed  Google Scholar 

  13. Sesso HD, Paffenbarger Jr RS, Lee IM . Alcohol consumption and risk of prostate cancer: the harvard alumni health study. Int J Epidemiol 2001; 30: 749–755.

    Article  CAS  PubMed  Google Scholar 

  14. Platz EA, Leitzmann MF, Rimm EB, Willett WC, Giovannucci E . Alcohol intake, drinking patterns, and risk of prostate cancer in a large prospective cohort study. Am J Epidemiol 2004; 159: 444–453.

    Article  PubMed  Google Scholar 

  15. Albertsen K, Gronbaek M . Does amount or type of alcohol influence the risk of prostate cancer? Prostate 2002; 52: 297–304.

    Article  PubMed  Google Scholar 

  16. Breslow RA, Wideroff L, Graubard BI, Erwin D, Reichman ME, Ziegler RG et al. Alcohol and prostate cancer in the NHANES I epidemiologic follow-up study. First national health and nutrition examination survey of the united states. Ann Epidemiol 1999; 9: 254–261.

    Article  CAS  PubMed  Google Scholar 

  17. Barba M, McCann SE, Schunemann HJ, Stranges S, Fuhrman B, De Placido S et al. Lifetime total and beverage specific—alcohol intake and prostate cancer risk: a case-control study. Nutr J 2004; 3: 23.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Schatzl G, Madersbacher S, Thurridl T, Waldmuller J, Kramer G, Haitel A et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 2001; 47: 52–58.

    Article  CAS  PubMed  Google Scholar 

  19. Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F et al. Finasteride and high-grade prostate cancer in the prostate cancer prevention trial. J Natl Cancer Inst 2007; 99: 1375–1383.

    Article  CAS  PubMed  Google Scholar 

  20. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R . Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646–649.

    Article  CAS  PubMed  Google Scholar 

  21. Akdogan M, Hassoun BS, Gurakar A, El-Sahwi K, Jazzar A, Wright H et al. Prostate-specific antigen levels among cirrhotic patients. Int J Biol Markers 2002; 17: 161–164.

    Article  CAS  PubMed  Google Scholar 

  22. Kubota Y, Sasagawa I, Sinzawa H, Kunii T, Itoh K, Miura H et al. Serum levels of free and total prostate-specific antigen in males with liver cirrhosis. Eur Urol 1999; 36: 409–412.

    Article  CAS  PubMed  Google Scholar 

  23. Cetinkaya M, Cetinkaya H, Ulusoy E, Baz S, Memis A, Yasa H et al. Effect of postnecrotic and alcoholic hepatic cirrhosis on development of benign prostatic hyperplasia. Prostate 1998; 36: 80–84.

    Article  CAS  PubMed  Google Scholar 

  24. Velicer CM, Kristal A, White E . Alcohol use and the risk of prostate cancer: results from the VITAL cohort study. Nutr Cancer 2006; 56: 50–56.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by the Department of Veterans Affairs, Department of Defense Prostate Cancer Research Program, the Georgia Cancer Coalition, the American Urological Association Foundation/Astellas Rising Star in Urology Award, National Institutes of Health R01 CA100938, and National Institutes of Health Specialized Programs of Research Excellence Grant P50 CA92131-01A1.

Author information

Authors and Affiliations

  1. Division of Urologic Surgery and the Duke Prostate Center, Department of Surgery, Duke University Medical Center and Urology Section, Veterans Affairs Medical Center, Durham, NC, USA

    L L Bañez & S J Freedland

  2. Department of Surgery, Section of Urology, Medical College of Georgia and Urology Section, Veterans Affairs Medical Center, Augusta, GA, USA

    R M Loftis & M K Terris

  3. Department of Pathology, Duke University Medical Center, Durham, NC, USA

    S J Freedland

  4. Department of Urology, Stanford University School of Medicine and Urology Section, Veterans Affairs Medical Center, Palo Alto, CA, USA

    J C Presti Jr

  5. Department of Urology, University of California Los Angeles School of Medicine and Urology Section, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA

    W J Aronson

  6. Division of Urology, Department of Surgery, Oregon Health and Science University, Portland, OR, USA

    C L Amling

  7. Department of Urology, University of California San Diego and Urology Section, Veterans Affairs Medical Center, San Diego, CA, USA

    C J Kane

Authors
  1. L L Bañez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R M Loftis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S J Freedland
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J C Presti Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W J Aronson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C L Amling
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C J Kane
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M K Terris
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L L Bañez.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bañez, L., Loftis, R., Freedland, S. et al. The influence of hepatic function on prostate cancer outcomes after radical prostatectomy. Prostate Cancer Prostatic Dis 13, 173–177 (2010). https://doi.org/10.1038/pcan.2010.3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2010.3

Keywords

This article is cited by

Search

Advanced search

Quick links